BioNTech stock rocketed Wednesday after rival Summit Therapeutics unveiled promising results for a novel approach to lung cancer treatment.Summit's Akeso-partnered drug, ivonescimab, works by blocking ...

The ability of tumours to induce new blood-vessel formation has been a major focus of cancer research over the past few decades, and vascular endothelial growth factor (VEGF) is now known to be ...

The U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab) for ...

Insufficient tissue supply with oxygen and nutrients triggers the release of growth factors, such as VEGF, that induce the formation of new vessel sprouts from the walls of preexisting ones.

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

Combining Trodelvy with Keytruda and pushing it into the frontline setting could “potentially double” the ADC’s market in ...

Ivonescimab plus chemotherapy improved survival in advanced squamous NSCLC vs tislelizumab and chemotherapy in a phase 3 ...

CEOs exercise warrants early, signaling bullish confidence ahead of a key Phase 3 trial data release. Read more here.

Analysts at BMO Capital Markets expect Summit and Akeso's HARMONi-6 readout to put some pressure on Merck and its blockbuster ...

The antibody targets both PD-1 and VEGF, aiming to release a key immune checkpoint and inhibit angiogenesis. Its molecular design includes an anti-VEGF antibody linked to two single-domain anti-PD ...

Oral presentation will feature AI-081, a potentially best-in-class PD-1/VEGF bispecific antibody and ONC-841, a first-in-class anti-Siglec-10 antibody Initial clinical data for both AI-081 and ONC-841 ...